Ehlers-Danlos Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major Ehlers-Danlos syndrome markets are expected to exhibit a CAGR of 3.42% during 2024-2034.
The Ehlers-Danlos syndrome market has been comprehensively analyzed in IMARC's new report titled "Ehlers-Danlos Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ehlers-Danlos syndrome refers to a group of genetic disorders that affect the body’s connective tissues, which provide support, strength, and structure to the skin, bones, blood vessels, and organs. This condition mainly occurs due to a defect in the production or processing of collagen, a protein that is a major component of connective tissue. As a result, these tissues become weak, loose, and fragile, leading to a variety of symptoms. Some of the common indications of the ailment may include joint hypermobility, fragile, stretchy and soft skin, easy bruising, chronic pain, fatigue, constipation, delayed wound healing, easy scarring, etc. In certain cases, individuals suffering from this disease may also experience abnormalities in the blood vessels, leading to an increased risk of cardiovascular complications, like aortic root dilation and arterial dissections. The diagnosis of Ehlers-Danlos syndrome is typically made through a combination of clinical evaluation, medical history, and other biochemical studies. A healthcare provider may also perform genetic testing to identify changes in DNA structure or chromosome sequence that can cause the underlying condition.
The rising cases of genetic disorders, causing mutations in genes that are involved in the production or processing of collagen are primarily driving the Ehlers-Danlos syndrome market. Furthermore, the inflating utilization of effective medications, such as nonsteroidal anti-inflammatory drugs, selective norepinephrine reuptake inhibitors, opioids, etc., to reduce pain and manage symptoms of the ailment is also propelling the market growth. In addition to this, the widespread adoption of physiotherapy, involving massages and stretching exercises for improving joint stability, strengthening muscles, and enhancing overall physical function, is further acting as another significant growth-inducing factor. Moreover, the escalating demand for custom-made ankle-foot orthotic devices on account of their several associated benefits, such as better walking ability, more efficient and coordinated movements, and reduced risk of falls or joint subluxations, is also creating a positive outlook for the market. Apart from this, the emerging popularity of regenerative injection therapy among patients with advanced disease, which stimulates the body to repair damaged joints and produce new collagen tissue, is expected to drive the Ehlers-Danlos syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Ehlers-Danlos syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Ehlers-Danlos syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ehlers-Danlos syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Ehlers-Danlos syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Ehlers-Danlos syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Ehlers-Danlos syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Ehlers-Danlos syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Ehlers-Danlos syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Ehlers-Danlos syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Ehlers-Danlos syndrome across the seven major markets?
What is the size of the Ehlers-Danlos syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Ehlers-Danlos syndrome?
What will be the growth rate of patients across the seven major markets?
Ehlers-Danlos Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Ehlers-Danlos syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ehlers-Danlos syndrome market?
What are the key regulatory events related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by status related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by phase related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Ehlers-Danlos syndrome market?
The Ehlers-Danlos syndrome market has been comprehensively analyzed in IMARC's new report titled "Ehlers-Danlos Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Ehlers-Danlos syndrome refers to a group of genetic disorders that affect the body’s connective tissues, which provide support, strength, and structure to the skin, bones, blood vessels, and organs. This condition mainly occurs due to a defect in the production or processing of collagen, a protein that is a major component of connective tissue. As a result, these tissues become weak, loose, and fragile, leading to a variety of symptoms. Some of the common indications of the ailment may include joint hypermobility, fragile, stretchy and soft skin, easy bruising, chronic pain, fatigue, constipation, delayed wound healing, easy scarring, etc. In certain cases, individuals suffering from this disease may also experience abnormalities in the blood vessels, leading to an increased risk of cardiovascular complications, like aortic root dilation and arterial dissections. The diagnosis of Ehlers-Danlos syndrome is typically made through a combination of clinical evaluation, medical history, and other biochemical studies. A healthcare provider may also perform genetic testing to identify changes in DNA structure or chromosome sequence that can cause the underlying condition.
The rising cases of genetic disorders, causing mutations in genes that are involved in the production or processing of collagen are primarily driving the Ehlers-Danlos syndrome market. Furthermore, the inflating utilization of effective medications, such as nonsteroidal anti-inflammatory drugs, selective norepinephrine reuptake inhibitors, opioids, etc., to reduce pain and manage symptoms of the ailment is also propelling the market growth. In addition to this, the widespread adoption of physiotherapy, involving massages and stretching exercises for improving joint stability, strengthening muscles, and enhancing overall physical function, is further acting as another significant growth-inducing factor. Moreover, the escalating demand for custom-made ankle-foot orthotic devices on account of their several associated benefits, such as better walking ability, more efficient and coordinated movements, and reduced risk of falls or joint subluxations, is also creating a positive outlook for the market. Apart from this, the emerging popularity of regenerative injection therapy among patients with advanced disease, which stimulates the body to repair damaged joints and produce new collagen tissue, is expected to drive the Ehlers-Danlos syndrome market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the Ehlers-Danlos syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for Ehlers-Danlos syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the Ehlers-Danlos syndrome market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the Ehlers-Danlos syndrome market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the Ehlers-Danlos syndrome market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current Ehlers-Danlos syndrome marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the Ehlers-Danlos syndrome market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the Ehlers-Danlos syndrome market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the Ehlers-Danlos syndrome market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of Ehlers-Danlos syndrome by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with Ehlers-Danlos syndrome across the seven major markets?
What is the size of the Ehlers-Danlos syndrome patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of Ehlers-Danlos syndrome?
What will be the growth rate of patients across the seven major markets?
Ehlers-Danlos Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for Ehlers-Danlos syndrome drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the Ehlers-Danlos syndrome market?
What are the key regulatory events related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by status related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by phase related to the Ehlers-Danlos syndrome market?
What is the structure of clinical trial landscape by route of administration related to the Ehlers-Danlos syndrome market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EHLERS-DANLOS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EHLERS-DANLOS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EHLERS-DANLOS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 EHLERS-DANLOS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EHLERS-DANLOS SYNDROME - UNMET NEEDS
10 EHLERS-DANLOS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 EHLERS-DANLOS SYNDROME - MARKETED PRODUCTS
11.1 List of Ehlers-Danlos Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EHLERS-DANLOS SYNDROME - PIPELINE DRUGS
12.1 List of Ehlers-Danlos Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 ACER 002 - Acer Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Enzastaurin - Aytu BioPharma/ Denovo Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EHLERS-DANLOS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EHLERS-DANLOS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EHLERS-DANLOS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ehlers-Danlos Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ehlers-Danlos Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ehlers-Danlos Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ehlers-Danlos Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ehlers-Danlos Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ehlers-Danlos Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ehlers-Danlos Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ehlers-Danlos Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
16 EHLERS-DANLOS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EHLERS-DANLOS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EHLERS-DANLOS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 EHLERS-DANLOS SYNDROME - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 EHLERS-DANLOS SYNDROME - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 EHLERS-DANLOS SYNDROME - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 EHLERS-DANLOS SYNDROME - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 EHLERS-DANLOS SYNDROME - UNMET NEEDS
10 EHLERS-DANLOS SYNDROME - KEY ENDPOINTS OF TREATMENT
11 EHLERS-DANLOS SYNDROME - MARKETED PRODUCTS
11.1 List of Ehlers-Danlos Syndrome Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 EHLERS-DANLOS SYNDROME - PIPELINE DRUGS
12.1 List of Ehlers-Danlos Syndrome Pipeline Drugs Across the Top 7 Markets
12.1.1 ACER 002 - Acer Therapeutics
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Enzastaurin - Aytu BioPharma/ Denovo Biopharma
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. EHLERS-DANLOS SYNDROME - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. EHLERS-DANLOS SYNDROME – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 EHLERS-DANLOS SYNDROME - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Ehlers-Danlos Syndrome - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Ehlers-Danlos Syndrome - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Ehlers-Danlos Syndrome - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Ehlers-Danlos Syndrome - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Ehlers-Danlos Syndrome - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Ehlers-Danlos Syndrome - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Ehlers-Danlos Syndrome - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Ehlers-Danlos Syndrome - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Ehlers-Danlos Syndrome - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Ehlers-Danlos Syndrome - Access and Reimbursement Overview
16 EHLERS-DANLOS SYNDROME - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 EHLERS-DANLOS SYNDROME MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 EHLERS-DANLOS SYNDROME MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
